Disease · MONDO_0005361
Comparisons in its trials23
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 23
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Oral Budesonide Suspension (OBS) vs Placebo: deaths from any cause | 0 of 213 | 0 of 105 | 318 | NCT02605837 | Trial comparisons |
| Oral Budesonide Suspension (OBS) vs Placebo: Number of Participants With Treatment-Emergent Adverse Events (AE) | 130 of 213 | 64 of 105 | 318 | NCT02605837 | Trial comparisons |
| Oral Budesonide Suspension (OBS) vs Placebo: serious adverse events | 2 of 213 | 1 of 105 | 318 | NCT02605837 | Trial comparisons |
| BOS-BOS vs PBO-BOS: Number of Participants With Clinically Significant Change From Baseline in Vital Signs | 0 of 121 | 0 of 10 | 131 | NCT03245840 | Trial comparisons |
| BOS-BOS vs PBO-BOS: Number of Participants With Clinically Significant Changes in Clinical Laboratory Assessments | 0 of 121 | 0 of 10 | 131 | NCT03245840 | Trial comparisons |
| BOS-BOS vs PBO-BOS: deaths from any cause | 2 of 121 | 0 of 10 | 131 | NCT03245840 | Trial comparisons |
| BOS-BOS vs PBO-BOS: serious adverse events | 11 of 121 | 0 of 10 | 131 | NCT03245840 | Trial comparisons |
| Dupilumab 300 mg QW vs Placebo: deaths from any cause | 0 of 23 | 0 of 24 | 47 | NCT02379052 | Trial comparisons |
| Dupilumab 300 mg QW vs Placebo: serious adverse events | 3 of 23 | 0 of 24 | 47 | NCT02379052 | Trial comparisons |
| Esomeprazole vs Budesonide: Participants With Presence of Erosive Esophagitis at Six Month Endoscopy | 1 of 18 | 8 of 28 | 46 | NCT00728481 | Trial comparisons |
| Esomeprazole vs Budesonide: Participants With Presence of Esophageal Rings/Furrows at Six Month Endoscopy | 11 of 18 | 17 of 28 | 46 | NCT00728481 | Trial comparisons |
| Esomeprazole vs Budesonide: serious adverse events | 0 of 18 | 0 of 28 | 46 | NCT00728481 | Trial comparisons |
| Flovent 1760 mcg vs Placebo: deaths from any cause | 0 of 28 | 0 of 14 | 42 | NCT00426283 | Trial comparisons |
| Flovent 1760 mcg vs Placebo: serious adverse events | 0 of 28 | 0 of 14 | 42 | NCT00426283 | Trial comparisons |
| Esomeprazole vs Swallowed Fluticasone: Number of Participants Who Responded | 7 of 21 | 4 of 21 | 42 | NCT00895817 | Trial comparisons |
| Esomeprazole vs Swallowed Fluticasone: serious adverse events | 0 of 21 | 0 of 21 | 42 | NCT00895817 | Trial comparisons |
| Oral Viscous Budesonide Plus Prevacid vs Placebo Plus Prevacid: deaths from any cause | 0 of 21 | 0 of 11 | 32 | NCT00638456 | Trial comparisons |
| Oral Viscous Budesonide Plus Prevacid vs Placebo Plus Prevacid: serious adverse events | 0 of 21 | 0 of 11 | 32 | NCT00638456 | Trial comparisons |
| Group A Receives Routine Care and Esophageal Dilatation vs Group B Receives SOC Only: serious adverse events | 0 of 17 | 0 of 14 | 31 | NCT00880906 | Trial comparisons |
| Omalizumab vs Placebo: serious adverse events | 0 of 15 | 0 of 15 | 30 | NCT00123630 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005361/comparisons